MAC15 RxPONDER trial presented at the San Antonio Breast Cancer Symposium

Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium.

More >>
 
Dr. Cheung and Dr. Hay receive bridge funding - CIHR Spring 2020 competition

Dr. Cheung and Dr. Hay receive bridge funding - CIHR Fall 2020 competition

Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received an additional $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Fall 2020 competition matching funds awarded in the spring from this program designed to capture and support ideas with the greatest potential to advance health-related knowledge in Canada. 

More >>
 
PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.

More >>
 
An interview with Senior Investigator Annette Hay

An interview with Senior Investigator Annette Hay

Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.

More >>
 

Planned trials

CXC2

Radiation Therapy and Cisplatin Alone or in Combination with Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

HD11

Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

I240

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

More >>

PAC3

Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Recently activated

CO29

Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer (DYNAMIC III)

More >>

HDC1

Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

More >>

MA40

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

More >>

OV26

Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy

More >>

PR21

PLUDO (Prostate Lutetium/Docetaxel): Study of 177Lu-PSMA-617 vs Docetaxel in Pts with Met Castration-Resistant Prostate Ca & PSMA-Positive Disease

More >>

PR22

Darolutamide Augments Standard Therapy for Localized High-Risk Prostate Cancer (DASL-HiCaP)

More >>

SR7

Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

More >>

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 
Pancreatic cancer patient Susan Stewart with her family, she enrolled in the CCTG PA.7 immunotherapy and chemotherapy trial

New pancreatic cancer trial provides hope to BC family

An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer – the deadliest cancer facing Canadians today.

More >>
 

Publications

Multiply robust subgroup identification for longitudinal data with dropouts via median regression

Journal of Multivariate Analysis 181: 104691, 2021
Lu W;Qin G;Zhu Z;Tu D;

More >>

Phase II Randomized Trial of Neoadjuvant Pembrolizumab +/- Chemotherapy for Operable Stage IA3-IIA Non-Small Cell Lung Cancer

J Thoracic Oncol , 2021
Huynh C;Rayes R;Gaudreau P;Hirsh V;Ofiara L;Owen S;Shieh B;Walsh L;Spicer J;

More >>

Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

J Clin Oncol 39, 2021
Renouf DJ;Loree JM;Knox JJ;Kavan P;Jonker DJ;Welch S;Couture F;Lemay F;Tehfe M;Harb M;Aucoin N;Ko Y;Tang PA;Topham JT;Jia S;Du P;Schaeffer DF;Gill S;Tu D;O'Callaghan CJ;

More >>

Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab + tremelimumab (D+T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

J Clin Oncol 39, 2021
Loree JM;Topham JT;Kennecke HF;Feilotter H;Keshavarz-Rahaghi F;Lee YS;Li W;Quinn K;Renouf DJ;Jonker DJ;Tu D;O'Callaghan CJ;

More >>

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study (ONLINE)

The Lancet Oncology , 2021
Mayer EL;Dueck AC;Martin M;Rubovszky G;Burstein HJ;Bellet-Ezquerra M;Miller KD;Zdenkowski N;Winer EP;Pfeiler G;Goetz M;Ruiz-Borrego M;Anderson D;Nowecki Z;Loibl S;Moulder S;Ring A;Fitzal F;Traina T;Chan A;Rugo HS;Lemieux J;Henao F;Lyss A;Novoa SA;Wolff AC;Vetter M;Egle D;Morris PG;Mamounas EP;Gil-Gil MJ;Prat A;Fohler H;Metzger Filho O;Schwarz M;DuFrane C;Fumagalli D;Theall KP;Lu DR;Bartlett CH;Koehler M;Fesl C;DeMichele A;Gnant M;

More >>

Integrating Patient-Centred Research in the Canadian Cancer Trials Group

Current Oncology 28: 630 - 639, 2021
Needham J;Taylor J;Nomikos D;

More >>

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer

J Clin Oncol 38: 3042 - 3050, 2020
Eastham JA;Heller G;Halabi S;Monk JP;Beltran H;Gleave M;Evans CP;Clinton SK;Szmulewitz RZ;Coleman J;Hillman DW;Watt CR;George S;Sanda MG;Hahn OM;Taplin ME;Parsons JK;Mohler JL;Small EJ;Morris MJ;

More >>